It's possible he will be right - he has obviously met with the FDA many times. Although it is his job to make the results look good and I note he has never managed to get a product approved by the FDA. Hopefully that all changes in the next couple of months with GVHD. I won't be surprised if the meetings re LVAD amount nothing though.
As I have said before I have put my money on the line for 2 reasons
- pending approval for GVHD
- (hopefully) positive results in chronic back pain
Anything else I would consider a bonus - I am certainly not holding my breath for approval in LVAD patients. Frankly I would rather we didn't waste valuable capital on it.
GVHD in US, page-53
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.015(1.01%) |
Mkt cap ! $1.741B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $17.68M | 11.78M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 161573 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 1425 | 3 |
View Market Depth
| Last trade - 15.59pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |